The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
The firm has launched both a public offering of common stock as well as a private placement of warrants, expecting to bring in around $20 million from the transactions.
The Royal Oaks, Michigan-based firm anticipates launching the assay — which currently analyzes 214 genes for prostate cancer risk — for research-use-only applications in H2 2020.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
